MARKET

ASMB

ASMB

Assembly Bioscie
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.190
+0.090
+4.29%
After Hours: 2.210 +0.02 +0.91% 16:29 07/01 EDT
OPEN
2.120
PREV CLOSE
2.100
HIGH
2.200
LOW
2.070
VOLUME
218.05K
TURNOVER
0
52 WEEK HIGH
3.940
52 WEEK LOW
1.320
MARKET CAP
105.59M
P/E (TTM)
-0.7868
1D
5D
1M
3M
1Y
5Y
U.S. Markets Open Lower; Winnebago Posts Upbeat Results
U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Wednesday.
Benzinga · 06/22 14:03
Assembly Biosciences Presents New Data Highlighting Clinical Progress Of Core Inhibitor Programs At EASL's International Liver Congress 2022
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced data
Benzinga · 06/22 12:02
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022
Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM​, an internationally-recognized hepatologist, and authority and investigator in hepatitis clinical trials SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWS...
GlobeNewswire · 06/21 12:00
Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases,...
GlobeNewswire · 06/08 12:00
What Type Of Shareholders Own The Most Number of Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares?
If you want to know who really controls Assembly Biosciences, Inc. ( NASDAQ:ASMB ), then you'll have to look at the...
Simply Wall St. · 06/08 11:58
Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection
Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection
Benzinga · 06/06 15:24
BRIEF-Assembly Biosciences Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor Abi-H3733
reuters.com · 06/06 12:39
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 For Treatment Of Chronic Hepatitis B Virus Infection
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced the
Benzinga · 06/06 12:02
More
No Data
Learn about the latest financial forecast of ASMB. Analyze the recent business situations of Assembly Bioscie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
40.00%Buy
40.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ASMB stock price target is 9.10 with a high estimate of 15.00 and a low estimate of 2.000.
High15.00
Average9.10
Low2.000
Current 2.190
EPS
Actual
Estimate
-0.53-0.40-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 98
Institutional Holdings: 21.17M
% Owned: 43.91%
Shares Outstanding: 48.22M
TypeInstitutionsShares
Increased
13
1.48M
New
9
374.56K
Decreased
19
3.14M
Sold Out
17
2.72M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
William Ringo
President/Chief Executive Officer/Director
John Mchutchison
Chief Financial Officer
Michael Samar
Chief Operating Officer
Jason Okazaki
Chief Scientific Officer
William Delaney
Other
Luisa Stamm
Other
Nicole White
Independent Director
Anthony Altig
Independent Director
Gina Consylman
Independent Director
Richard DiMarchi
Independent Director
Michael Houghton
Independent Director
Lisa Johnson-pratt
Independent Director
Susan Mahony
No Data
No Data
About ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.